The Probable Reason Behind NovoCure's Double-Digit Drop Today [The Motley Fool]
NovoCure Limited - Ordinary Shares (NVCR)
Last novocure limited - ordinary shares earnings: 4/30 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
novocure.com/investor-relations
Company Research
Source: The Motley Fool
Shares retreat after the company releases details about an upcoming phase 3 trial. Should investors be worried, or is this just market noise? Brian Feroldi ( TMFTypeoh ) Jun 4, 2018 at 10:37AM What happened After the company announced details of its phase 3 INNOVATE-3 trial at the American Society of Clinical Oncology (ASCO) annual meeting, shares of NovoCure ( NASDAQ:NVCR ) , a red-hot medical device company focused on cancer , fell as much as 12% in early morning trading today. Shares were down about 10% as of 10:30 a.m. EDT. So what The INNOVATE-3 trial is a late-stage program designed to test NovoCure's Optune device in combination with paclitaxel (more commonly known as Celgene 's drug Abraxane) as a treatment for recurrent, platinum-resistant ovarian cancer. Image source: Getty Images. Here are a few of the key details of the s
Show less
Read more
Impact Snapshot
Event Time:
NVCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVCR alerts
High impacting NovoCure Limited - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NVCR
News
- NovoCure Limited Q1 Earnings: Core Business Accelerating [Seeking Alpha]Seeking Alpha
- NovoCure Limited (NASDAQ: NVCR) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $21.00 price target on the stock.MarketBeat
- NovoCure Limited (NASDAQ: NVCR) had its price target lowered by analysts at HC Wainwright from $24.00 to $22.00. They now have a "neutral" rating on the stock.MarketBeat
- Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from PharmakonBusiness Wire
- Novocure Reports First Quarter 2024 Financial ResultsBusiness Wire
NVCR
Earnings
- 5/2/24 - Beat
NVCR
Sec Filings
- 5/2/24 - Form 10-Q
- 5/2/24 - Form 8-K
- 4/22/24 - Form DEFA14A
- NVCR's page on the SEC website